Browsing Tag
Amgen
64 posts
Aclaris Therapeutics prices $50m share offering following positive ATI-052 trial results
Aclaris Therapeutics targets $50M financing after ATI-052 trial success. Explore its cash position, dilution risks and Phase 2b strategy.
Mattel changed its CEO, now its CFO. What does Peter Griffith need to fix next?
Mattel has recruited former Amgen finance chief Peter Griffith weeks after installing Roger Lynch as CEO, creating a new leadership pairing as the Barbie and Hot Wheels owner balances revenue growth, weaker margins, entertainment expansion and aggressive capital allocation.
DEGEVMA approval strengthens Teva biosimilar pipeline as company shifts beyond traditional generics
Teva wins FDA approval for DEGEVMA, expanding its U.S. denosumab biosimilar portfolio as competition intensifies around Xgeva.
Amgen data breach: Patient records exposed via third-party cloud storage
Amgen said patient health data was exfiltrated via third-party cloud storage in an incident deemed material days before its August 4 Q2 earnings release.
TScan launches Phase 3 ALLOHA-2 with $128m in cash and a looming funding gap
TSC-101 enters Phase 3 as TScan weighs promising donor-chimerism data against manufacturing complexity and a pre-readout funding gap.
Takeda’s zasocitinib shows high clearance rates at difficult psoriasis sites
Scalp and palmoplantar clearance rates approached 70% to 77%, but regulatory review, safety labelling and market access will determine the commercial impact.
Chemomab Therapeutics (CMMB) and Scipher Medicine to merge in $150m reverse deal
Scipher Medicine and Chemomab are merging in all-stock deal, taking Scipher public via reverse merger. $30M PIPE led by Northpond. Q4 2026 close, H1 2028 Phase 2 data.
Vertex (VRTX) to enter endocrine diseases with $10bn Crinetics acquisition, targets $5bn peak revenue by 2029
Vertex Pharmaceuticals to acquire Crinetics for $10 billion at 102% premium, largest deal in VRTX history. Read the full analysis.
Viridian Therapeutics (VRDN) challenges Amgen’s Tepezza with broader thyroid eye disease approval
Viridian Therapeutics wins FDA approval for Lumvoa, its first commercial product, challenging Amgen in thyroid eye disease.
Why Amgen’s Tavneos trouble may be more than just another FDA safety review
Find out why Amgen’s Tavneos review could reshape rare disease drug regulation, investor sentiment, and biotech M&A risk.